USING THE POTENTIAL OF MYCOBACTERIOPHAGES TO COMBAT TUBERCULOSIS: FROM CRISIS TO CURE
Keywords:
Mycobacterium tuberculosis, diagnosing, propertie, bioengineering fieldAbstract
Mycobacterium tuberculosis (Mtb) is an intracellular pathogen that primarily affecting the lungs and causing tuberculosis (TB), a fatal and highly destructive illness that poses a vitally important global disease burden. In addition, Mtb can infect any organ in the body, causing other lethal diseases such as tuberculous meningitis, tuberculoma miliary TB, tuberculous abscess, tuberculous encephalopathy, and even intracranial hemorrhage [1]. TB is recognized as a significant global health concern, graded by the World Health Organization (WHO) as the 10th cause of death worldwide .
References
Bessesen MT, Shlay J, Stone-Venohr B, Cohn DL, Reves RR. Disseminated Mycobacterium genavense infection: clinical and microbiological features and response to therapy. AIDS. 1993; 7:1357–61. http://dx.doi.org/10.1097/00002030-199310000-00009
Hoefsloot W, van Ingen J, Peters EJ, Magis-Escurra C, Dekhuijzen PN, Boeree MJ, et al. Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases. Clin Microbiol Infect. 2013;19:432–7. http://dx.doi.org/10.1111/ j.1469-0691.2012.03817.x
Charles P, Lortholary O, Dechartres A, Doustdar F, Viard JP, Lecuit M, et al.; French Mycobacterium genavense Study Group. Mycobacterium genavense infections: a retrospective multicenter study in France, 1996–2007. Medicine (Baltimore). 2011;90:223– 30. http://dx.doi.org/10.1097/MD.0b013e318225ab89
Pai S, Esen N, Pan X, Musser JM. Routine rapid Mycobacterium species assignment based on species-specific allelic variation in the 65-kilodalton heat shock protein gene (hsp65). Arch Pathol Lab Med. 1997;121:859–64.
Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367:725–34. http://dx.doi.org/10.1056/NEJMoa1111160
Chi CY, Lin CH, Ho MW, Ding JY, Huang WC, Shih HP, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore). 2016;95:e3927. http://dx.doi.org/10.1097/ MD.0000000000003927
Valour F, Perpoint T, Sénéchal A, Kong XF, Bustamante J, Ferry T, et al.; Lyon TB Study Group. Interferon-γ autoantibodies as predisposing factor for nontuberculous mycobacterial infection. Emerg Infect Dis. 2016;22:1124–6. http://dx.doi.org/10.3201/ eid2206.151860
Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood. 2012;119:3933–
http://dx.doi.org/10.1182/ blood-2011-12-395707 9. Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis. 2009;15:1351–8, quiz 1544. http://dx.doi.org/ 10.3201/eid1509.081259
